Viking Therapeutics to Participate at Upcoming Investor Conferences
Rhea-AI Summary
Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biopharmaceutical company developing therapies for metabolic and endocrine disorders, has announced its participation in four upcoming investor conferences in September 2025.
The company will attend the Cantor Global Healthcare Conference (Sept 3-5), Morgan Stanley Global Healthcare Conference (Sept 8-10), Bernstein Healthcare Forum (Sept 23-25), and Stifel Virtual Cardiometabolic Forum (Sept 30). Management will engage in fireside chats, presentations, and investor meetings.
Live webcasts will be available for the Morgan Stanley and Bernstein events through Viking's website, with replays accessible afterward in the Investors & Media section.
Positive
- None.
Negative
- None.
News Market Reaction 10 Alerts
On the day this news was published, VKTX declined 1.92%, reflecting a mild negative market reaction. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $62M from the company's valuation, bringing the market cap to $3.15B at that time.
Data tracked by StockTitan Argus on the day of publication.
Details of the company's participation are as follows:
- Cantor Global Healthcare Conference
Details: Viking management will participate in a fireside chat and in investor meetings
Conference Date: September 3-5, 2025
Fireside Chat Time: 9:45 – 10:15 a.m. Eastern on Friday, September 5, 2025
Location:New York, NY
- Morgan Stanley 23rd Annual Global Healthcare Conference
Details: Viking management will participate in a fireside chat and in investor meetings
Conference dates: September 8-10, 2025
Fireside Chat Time: 3:20 – 3:55 p.m. Eastern on Monday, September 8, 2025, webcast available
Location:New York, NY
- Bernstein's 2nd Annual Healthcare Forum
Details: Viking management will deliver a corporate presentation and participate in investor meetings
Conference Dates: September 23-25, 2025
Presentation Time: 11:20 a.m. – 12:00pm Eastern on Tuesday, September 23, 2025, webcast available
Location:New York, NY
- Stifel Virtual Cardiometabolic Forum
Details: Viking management will participate in a fireside chat and in investor meetings
Conference Date: September 30, 2025
Location: Virtual
Live webcasts of the Morgan Stanley fireside chat and the Bernstein presentation may be accessed via a link on the Viking Therapeutics website in the Investors & Media section under Webcasts. Additionally, replays of the webcasts will be available on the Viking website following the conferences.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. The company is evaluating its subcutaneous formulation of VK2735 in a Phase 3 obesity program that includes two Phase 3 clinical trials (VANQUISH-1 and VANQUISH-2). Data from a Phase 1 and a Phase 2 trial evaluating subcutaneous VK2735 demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in a Phase 2 trial in obesity. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders. In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids, as compared to placebo.
For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-participate-at-upcoming-investor-conferences-302541472.html
SOURCE Viking Therapeutics, Inc.
FAQ
When is Viking Therapeutics (VKTX) presenting at the Morgan Stanley Healthcare Conference 2025?
How can investors access Viking Therapeutics' (VKTX) conference presentations?
Which investor conferences is Viking Therapeutics (VKTX) attending in September 2025?
What type of company is Viking Therapeutics (VKTX)?
